HomeCategoryScience - Verséa

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/10/PMA-Booth-Backdrop-v2-Copy-1.png?resize=1280%2C640&ssl=1

At the upcoming International Fresh Produce Association (IFPA) Global Produce & Floral Show taking place in Orlando (FL) from October 27th to 29th 2022,  Verséa Holdings, Inc. is officially launching a new business division Verséa AgroTech and its proprietary next-generation Extended Shelf-life Packaging (ESP) System. Dr Perry D. Lidster, Ph.D., the Chief Scientific Officer of...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/USF-Fair.jpg?resize=847%2C640&ssl=1

Verséa is looking for this year’s brightest students and recent graduates to join our Paid Internship Program! Today we are at the University of Tampa searching for ambitious individuals who wish to gain professional experience in Marketing & Business Development at one of the fastest-growing healthcare companies in the U.S. CONTACT US TODAY at 1.813.345.2185...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/outlined-blue-eye.jpg?resize=960%2C350&ssl=1

“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.”   Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), signed exclusive...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/08/versea-occular-eye-technology-blue-3x1-1-e1661466967859.jpg?resize=711%2C399&ssl=1

Verséa Holdings, Inc. (“Verséa”) welcomes Rob Sambursky, MD, who joined the company as the President, effective as of August 5, 2022. Dr. Sambursky will support corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business division, Verséa Ophthalmics, with a goal of providing innovative...

https://i0.wp.com/www.versea.com/wp-content/uploads/2021/03/women-in-science-l.jpg?resize=1200%2C640&ssl=1

Verséa Discovery successfully ran its first validation test assays at the UCSD Biomedical Lab using its proprietary VCX™ Discovery Platform   The cellular based platform VCX™ Discovery Platform follows a proprietary process developed by Verséa Discovery. Through machine learning, the system links highly specific cellular functions (focused on mitochondrial biology and second messenger signaling) to...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/03/vision-concept_800-e1648064890754.jpg?resize=800%2C464&ssl=1

A recently published peer-reviewed scientific article “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma” has provided insight into unique therapeutic potential of Cannabinol (CBN) for glaucoma treatment   The article, published in a leading international journal Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease) (LINK to the article)...